

Participants wanted for a research study at the
University of California San Francisco:

Microbiota Intervention to Change the Response in Parkinson's Disease (Micro-PD)

Overview: The bacteria that live in our gastrointestinal system, collectively known as the gut microbiome, may be abnormal in Parkinson's disease, and may contribute to worsening symptoms and disease. The Micro-PD study is trying to understand the role of "resetting" the gut microbiome in Parkinson's disease.

What are we testing?

Rifaximin is an antibiotic that does not enter the blood stream but is active in the intestine. It may be able to reduce bacteria in the gut that can make oral levodopa less effective. We are testing whether or not treatment with rifaximin can improve your response to levodopa.

Who is eligible?

- People with Parkinson's with onset after age 30
- Taking levodopa preparations (including carbidopa / levodopa, Sinemet, or Rytary)
- Having at least 1.5 hours of time during the day when medications are not working well
- Additional criteria will be reviewed with study personnel

What is involved?

- Total duration of the study is 6-8 weeks
- 3 in-office visits and 4 telephone calls
- Treatment with either rifaximin or a placebo

Compensation: You will be given a stipend towards the costs of travel to UCSF.

Contact: If you or someone you know may qualify, please call Ethan Brown at
415-514-6257